Ipca Laboratories Ltd vs Sun Pharmaceutical Industries Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Jun 13, 2026

Key Highlights

The Latest Trading Price of Ipca Laboratories Ltd is ₹ 1585 as of 12 Jun 15:30 . The P/E Ratio of Ipca Laboratories Ltd changed from 21.2 on March 2021 to 51.6 on March 2025 . This represents a CAGR of 19.47% over 5 yearsThe P/E Ratio of Sun Pharmaceutical Industries Ltd changed from 49.4 on March 2021 to 38.1 on March 2025 . This represents a CAGR of -5.06% over 5 years The Market Cap of Ipca Laboratories Ltd changed from ₹ 24137 crore on March 2021 to ₹ 38088 crore on March 2025 . This represents a CAGR of 9.55% over 5 yearsThe Market Cap of Sun Pharmaceutical Industries Ltd changed from ₹ 143384 crore on March 2021 to ₹ 416392 crore on March 2025 . This represents a CAGR of 23.77% over 5 years The revenue of Ipca Laboratories Ltd for the Mar '26 is ₹ 2482 crore as compare to the Dec '25 revenue of ₹ 2430 crore. This represent the growth of 2.13% The revenue of Sun Pharmaceutical Industries Ltd for the Mar '26 is ₹ 15070 crore as compare to the Dec '25 revenue of ₹ 16099 crore. This represent the decline of -6.39% The ebitda of Ipca Laboratories Ltd for the Mar '26 is ₹ 531.79 crore as compare to the Dec '25 ebitda of ₹ 571.19 crore. This represent the decline of -6.9% The ebitda of Sun Pharmaceutical Industries Ltd for the Mar '26 is ₹ 4412 crore as compare to the Dec '25 ebitda of ₹ 5037 crore. This represent the decline of -12.41% The net profit of Ipca Laboratories Ltd changed from ₹ 198.98 crore to ₹ 309.4 crore over 8 quarters. This represents a CAGR of 24.70% The net profit of Sun Pharmaceutical Industries Ltd changed from ₹ 2871 crore to ₹ 2723 crore over 8 quarters. This represents a CAGR of -2.60% The Dividend Payout of Ipca Laboratories Ltd changed from 8.9 % on March 2021 to 15.59 % on March 2025 . This represents a CAGR of 11.86% over 5 yearsThe Dividend Payout of Sun Pharmaceutical Industries Ltd changed from 213.61 % on March 2021 to 89.64 % on March 2025 . This represents a CAGR of -15.94% over 5 years .

About Ipca Laboratories Ltd

Ipca Laboratories Limited (IPCA) was incorporated on 19 October, 1949 under the name of 'The Indian Pharmaceutical Combine Association Limited.' Ipca is a fully integrated, pharmaceutical company manufacturing and marketing over 350 formulations and 80 API's covering various therapeutic segments.
The products of the Company are now sold in over 100 countries across the globe.
The Company has 18 manufacturing units in India manufacturing API's and formulations for the world market. Ipca's APIs and Formulations produced at world class manufacturing facilities are approved by leading drug regulatory authorities including the US-Food and Drug Administration (FDA), UK-Medicines and Healthcare products Regulatory Agency (MHRA), South Africa-Medicines Control Council (MCC), Brazil-Brazilian National Health Vigilance Agency (ANVISA) and Australia-Therapeutic Goods Administration (TGA) with operations in over 100 countries.

About Sun Pharmaceutical Industries Ltd

Sun Pharmaceutical Industries Limited including its subsidiaries and associates is the fourth largest global specialty generic company that is ranked No. 1 in India and No. 8 in the US. It is the largest Indian pharmaceutical company in the US and among the leading Indian pharmaceutical companies in emerging markets.
The company manufactures and markets a large basket of pharmaceutical formulations covering a broad spectrum of chronic and acute therapies.
It includes generics, branded generics, complex or difficult to make technology intensive products, over-the-counter (OTC) products, anti-retrovirals (ARVs), Active Pharmaceutical Ingredients (APIs) and intermediates.
The product portfolio of over 2000 high quality molecules covers multiple dosage forms, including tablets, capsules, injectables, sprays, inhalers, drug delivery systems, ointments, creams and liquids.

FAQs for the comparison of Ipca Laboratories Ltd and Sun Pharmaceutical Industries Ltd

Which company has a larger market capitalization, Ipca Laboratories Ltd or Sun Pharmaceutical Industries Ltd?

Market cap of Ipca Laboratories Ltd is 40,232 Cr while Market cap of Sun Pharmaceutical Industries Ltd is 433,619 Cr

What are the key factors driving the stock performance of Ipca Laboratories Ltd and Sun Pharmaceutical Industries Ltd?

The stock performance of Ipca Laboratories Ltd and Sun Pharmaceutical Industries Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Ipca Laboratories Ltd and Sun Pharmaceutical Industries Ltd?

As of June 13, 2026, the Ipca Laboratories Ltd stock price is INR ₹1585.8. On the other hand, Sun Pharmaceutical Industries Ltd stock price is INR ₹1807.25.

How do dividend payouts of Ipca Laboratories Ltd and Sun Pharmaceutical Industries Ltd compare?

To compare the dividend payouts of Ipca Laboratories Ltd and Sun Pharmaceutical Industries Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.